Hepatitis B–related hepatic events after allogeneic HCT group 1 and 2 patients
Patient no. . | Recipients . | Donors . | HBV-related hepatitis . | Recipients' last follow-up HBV serology . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HBsAg/HBeAg/ Anti-HBe/ Anti-HBs . | HBV DNA bDNA/PCR . | A1896 . | T1762 and A1764 . | HBsAg/HBeAg/ HBeAb . | HBV DNA bDNA/PCR . | A1896 . | T1762 and A1764 . | Acute/ Chronic . | Severity . | HBsAg/HBeAg/ AntiHBe/ Anti-HBs . | |
Group 1 | |||||||||||
HBsAg-positive recipients | |||||||||||
1 | +/+/−/ND | +/+ | +/+/− | −/+ | Acute | Anicteric | +/+/−/ND | ||||
2 | +/+/−/ND | +/+ | +/−/+ | −/+ | +/−/−/ND | ||||||
3 | +/−/+/ND | +/+ | +/−/+ | +/−/+/ND | |||||||
4 | +/−/+/ND | −/+ | − | + | +/−/+ | +/−/+/ND | |||||
5 | +/−/+/ND | −/+ | + | + | +/−/+ | −/+ | − | + | Chronic | Anicteric | +/−/+/ND |
6 | +/−/+/ND | +/+ | + | + | +/−/+ | +/+ | + | − | Chronic | HF3-151 | +/−/+/ND |
7 | +/−/+/ND | −/+ | +/+/− | −/+ | Chronic | HF3-151 | +/−/+/ND | ||||
8 | +/−/+/ND | −/+ | − | + | +/−/+ | +/+/+/ND | |||||
9 | +/−/+/ND | −/+ | + | − | +/+/− | −/+ | +/+/+/ND | ||||
HBsAg negative recipients | |||||||||||
10 | −/ND/ND/+ | −/+ | −/ND/ND/+ | ||||||||
11 | −/ND/ND/+ | +/+/− | +/+ | −/ND/ND/+3-150 | |||||||
12 | −/ND/ND/+ | +/−/+ | −/ND/ND/+ | ||||||||
13 | −/ND/ND/+ | +/−/+ | +/+ | + | − | Chronic | HF3-151 | +/+/ND/ND | |||
14 | −/ND/ND/+ | +/+/− | +/+ | Chronic | HF3-151 | +/+/ND/ND | |||||
15 | −/ND/ND/− | +/−/+ | +/+ | + | + | Acute | HF | −/ND/ND/−3-150 | |||
16 | −/ND/ND/+ | +/−/+ | +/+ | + | + | Acute | HF | +/+/ND/ND | |||
17 | −/ND/ND/− | +/−/+ | −/ND/ND/− | ||||||||
18 | −/ND/ND/− | +/−/+ | −/ND/ND/− | ||||||||
Group 2 | |||||||||||
HBsAg positive recipients | |||||||||||
19 | +/+/−/ND | +/+ | − | − | −/+ | + | − | Acute | Anicteric | +/+/−/ND | |
20 | +/+/−/ND | +/+ | − | − | −/+ | +/−/−/ND | |||||
21 | +/+/−/ND | +/+ | − | − | Acute | Anicteric | +/+/−/ND | ||||
22 | +/+/−/ND | +/+ | − | + | +/+/−/ND | ||||||
23 | +/+/−/ND | +/+ | − | − | +/− | +/+/−/ND | |||||
24 | +/−/+/ND | −/+ | + | − | +/+ | −/+ | −/−/ND/+ | ||||
25 | +/−/+/ND | −/− | +/+ | −/−/ND/+ | |||||||
26 | +/−/+/ND | −/+ | + | + | +/+ | −/−/ND/+ | |||||
27 | +/−/+/ND | −/− | +/+ | +/−/+/ND | |||||||
HBsAg negative recipients | |||||||||||
28 | −/ND/ND/+ | −/− | −/ND/ND/+ | ||||||||
29 | −/ND/ND/+ | −/− | −/ND/ND/+ | ||||||||
30 | −/ND/ND/+ | −/− | +/− | −/ND/ND/+ | |||||||
31 | −/ND/ND/+ | −/− | +/+ | −/ND/ND/+ | |||||||
32 | −/ND/ND/− | −/− | −/ND/ND/− | ||||||||
33 | −/ND/ND/− | −/− | +/− | −/−/ND/+ | |||||||
34 | −/ND/ND/− | −/− | −/ND/ND/− | ||||||||
35 | −/ND/ND/− | −/− | +/− | −/−/ND/+ | |||||||
36 | −/ND/ND/− | −/− | −/ND/ND/− |
Patient no. . | Recipients . | Donors . | HBV-related hepatitis . | Recipients' last follow-up HBV serology . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HBsAg/HBeAg/ Anti-HBe/ Anti-HBs . | HBV DNA bDNA/PCR . | A1896 . | T1762 and A1764 . | HBsAg/HBeAg/ HBeAb . | HBV DNA bDNA/PCR . | A1896 . | T1762 and A1764 . | Acute/ Chronic . | Severity . | HBsAg/HBeAg/ AntiHBe/ Anti-HBs . | |
Group 1 | |||||||||||
HBsAg-positive recipients | |||||||||||
1 | +/+/−/ND | +/+ | +/+/− | −/+ | Acute | Anicteric | +/+/−/ND | ||||
2 | +/+/−/ND | +/+ | +/−/+ | −/+ | +/−/−/ND | ||||||
3 | +/−/+/ND | +/+ | +/−/+ | +/−/+/ND | |||||||
4 | +/−/+/ND | −/+ | − | + | +/−/+ | +/−/+/ND | |||||
5 | +/−/+/ND | −/+ | + | + | +/−/+ | −/+ | − | + | Chronic | Anicteric | +/−/+/ND |
6 | +/−/+/ND | +/+ | + | + | +/−/+ | +/+ | + | − | Chronic | HF3-151 | +/−/+/ND |
7 | +/−/+/ND | −/+ | +/+/− | −/+ | Chronic | HF3-151 | +/−/+/ND | ||||
8 | +/−/+/ND | −/+ | − | + | +/−/+ | +/+/+/ND | |||||
9 | +/−/+/ND | −/+ | + | − | +/+/− | −/+ | +/+/+/ND | ||||
HBsAg negative recipients | |||||||||||
10 | −/ND/ND/+ | −/+ | −/ND/ND/+ | ||||||||
11 | −/ND/ND/+ | +/+/− | +/+ | −/ND/ND/+3-150 | |||||||
12 | −/ND/ND/+ | +/−/+ | −/ND/ND/+ | ||||||||
13 | −/ND/ND/+ | +/−/+ | +/+ | + | − | Chronic | HF3-151 | +/+/ND/ND | |||
14 | −/ND/ND/+ | +/+/− | +/+ | Chronic | HF3-151 | +/+/ND/ND | |||||
15 | −/ND/ND/− | +/−/+ | +/+ | + | + | Acute | HF | −/ND/ND/−3-150 | |||
16 | −/ND/ND/+ | +/−/+ | +/+ | + | + | Acute | HF | +/+/ND/ND | |||
17 | −/ND/ND/− | +/−/+ | −/ND/ND/− | ||||||||
18 | −/ND/ND/− | +/−/+ | −/ND/ND/− | ||||||||
Group 2 | |||||||||||
HBsAg positive recipients | |||||||||||
19 | +/+/−/ND | +/+ | − | − | −/+ | + | − | Acute | Anicteric | +/+/−/ND | |
20 | +/+/−/ND | +/+ | − | − | −/+ | +/−/−/ND | |||||
21 | +/+/−/ND | +/+ | − | − | Acute | Anicteric | +/+/−/ND | ||||
22 | +/+/−/ND | +/+ | − | + | +/+/−/ND | ||||||
23 | +/+/−/ND | +/+ | − | − | +/− | +/+/−/ND | |||||
24 | +/−/+/ND | −/+ | + | − | +/+ | −/+ | −/−/ND/+ | ||||
25 | +/−/+/ND | −/− | +/+ | −/−/ND/+ | |||||||
26 | +/−/+/ND | −/+ | + | + | +/+ | −/−/ND/+ | |||||
27 | +/−/+/ND | −/− | +/+ | +/−/+/ND | |||||||
HBsAg negative recipients | |||||||||||
28 | −/ND/ND/+ | −/− | −/ND/ND/+ | ||||||||
29 | −/ND/ND/+ | −/− | −/ND/ND/+ | ||||||||
30 | −/ND/ND/+ | −/− | +/− | −/ND/ND/+ | |||||||
31 | −/ND/ND/+ | −/− | +/+ | −/ND/ND/+ | |||||||
32 | −/ND/ND/− | −/− | −/ND/ND/− | ||||||||
33 | −/ND/ND/− | −/− | +/− | −/−/ND/+ | |||||||
34 | −/ND/ND/− | −/− | −/ND/ND/− | ||||||||
35 | −/ND/ND/− | −/− | +/− | −/−/ND/+ | |||||||
36 | −/ND/ND/− | −/− | −/ND/ND/− |